Market Forecast By Regions (North America, Latin America, Asia Pacific, Europe, Middle East and Africa), By Type (Normal, DEBs, Cutting, Scoring), By Application (Coronary, Peripheral), By End-Use (ASCs, Hospitals, Cath Labs) And Competitive Landscape
Product Code: ETC150174 | Publication Date: Dec 2021 | Updated Date: Mar 2025 | Product Type: Report | |
Publisher: 6Wresearch | No. of Pages: 300 | No. of Figures: 90 | No. of Tables: 30 | |
Report Name | Angioplasty Balloons Market |
Forecast Period | 2025-2031 |
Market Size | USD 3.4 billion |
CAGR | 3.8% |
Growing Sector | Drug-Eluting Balloons (DEBs) |
The Angioplasty Balloons Market report provides a detailed analysis of various market segments, including product types, applications, end-users, and regions. It offers an unbiased and comprehensive examination of current market trends, high-growth areas, and key market drivers, enabling stakeholders to align their strategies with the evolving market dynamics.
The global angioplasty balloons market had a valuation of USD 2.71 billion in 2025. The rise in cardiovascular diseases worldwide, especially coronary artery disease, was the main factor to the growth of the market as it increased the need for minimally invasive procedures like angioplasty. The release of drug-eluting balloons, one of the major improvements in balloon technology, that help in the progress of the market by getting patients better outcomes and reducing restenosis rates.
The expansion of this market is contingent upon factors including the continuing surge of cardiovascular diseases, progressive breakthroughs in balloon design and a mounting inclination of less invasive surgical procedures. The market is forecasted to grow to USD 3.4 billion by 2031, and drug-eluting balloons are likely to become a major player in the all-year growth.
According to 6Wresearch, the global angioplasty balloons market is anticipated to grow at a CAGR of 3.8% during the forecast period 2025-2031. The angioplasty balloons market is, in essence, being driven by the escalating prevalence of cardiovascular diseases globally. Sedentary lifestyles, unhealthy diets, and an aging population have contributed to a higher incidence of conditions such as coronary artery disease, necessitating effective treatment options like angioplasty. This surge in cardiovascular cases has led to an increase in the number of angioplasty procedures but also in that of the angioplasty balloons market. Furthermore, technological advances have been one of the main players that have been responsible for shaping the market. The market has been greatly improved by the new methods of treatment like, for instance, drug-eluting balloons that are designed to release antiproliferative drugs to avoid restenosis. Not only have these innovations allowed for better patient outcomes but also have they decreased the need for further treatments, also being a major driving force behind the market's growth. This trend is reflected in the Angioplasty Balloons Market Growth.
Nevertheless, the market is coping with challenges, such as the high cost of advanced angioplasty and the stringent regulatory requirements for product approvals. These factors can hinder the entry of new products into the market and limit the adoption of innovative technologies, especially in developing regions with limited healthcare budgets. Moreover, the risk of the complications that are associated with angioplasty procedures and the challenges tied to market growth arise. Apart from this, the presence of other treatments like the coronary artery bypass grafting (CABG) surgery is another issue that is mainly felt in the angioplasty balloons market. Although angioplasty is an invasive procedure and some patients may be better off with surgical interventions according to the severity and location of blockages, it is still required to have continuous innovation and clinical trials in order to show the safety and efficacy of angioplasty balloons in various patient populations.
An interesting development in the angioplasty balloons market is the major increase in the use of drug-eluting balloons (DEBs). DEBs have got the attention of the users due to their capability to directly bring antiproliferative drugs to the vessel wall, thus, reducing the risk of restenosis without the need to implant a permanent stent. This tendency is likely to continue as the clinical evidence supporting the efficacy of DEBs and thus, healthcare providers looking for alternatives to stent implantation become more and more available.
Another emerging trend is the invention of qualified balloons planned for tough lesions, for instance, calcified and bifurcated lesions. The makers are now keying on producing balloons, which entail substantial flexibility, navigability, and deliverability features to virtually all problematic anatomies. These specialized balloons are designed to cut down procedural failure rates and thus the efficacy of angioplasty is thereby improved as it covers a much wider range of patients with complex coronary or peripheral artery disease.
The angioplasty balloons market is one that is full of investment opportunities. Companies are investing in the development of a variety of innovative balloon technologies such as Coated Balloons. In this section, we will concentrate on drug-coated balloons, for they are marketed as cost-effective, user-friendly solutions for local delivery of drugs.
Moving on, growth in new markets is spotted in the Asia-Pacific region, particularly China, is likely to become the most promising place on the planet, thus must be your top pick to invest in the stock market. This will not only aid in the production of more angioplasty balloons but will also increase the distribution network in the regions, thus, strengthening the angioplasty procedures demand. Not only this but also, they should put an effort to build strong relationships with local healthcare providers and regulatory agencies to enter and scale up the market in these countries.
Angioplasty balloon market is a midsized, homogeneous market characterized by a handful of players such as Medtronic, Boston Scientific Corporation, Johnson & Johnson Services, Inc. and B. Braun Melsungen AG. These companies leverage either product innovation or strategic partnerships or even acquisitions to solidify their market positions. Among the manufacturers of drug-eluting balloons and specialized angioplasty balloons for complex procedures, Medtronic and Boston Scientific are pursuing the aforementioned drug technology thus they are in the lead. On the other hand, the price of angioplasty balloons is continually dropping as new companies are coming in with new, less sophisticated technology, thus growing the competition.
Government regulatory factions in the angioplasty balloons market are vital as the regulatory body is the one that verifies that these medical devices are safe, effective, and of good quality. In the United States, the FDA categorizes angioplasty balloons as Class III medical devices, conducting very long clinical trials and seeking approvals before they are made available on the market. This rigorous regulatory process has been beneficial in terms of increasing patient safety; however, the side effect is that the time and costs related to entry of new products to the market have gone up. In Europe, the MDR (Medical Device Regulation) has taken over the previous MDD (Medical Device Directive) and has thus brought in stricter rules for product endorsement. The manufacturers are required to submit clinical data that show an enhanced improvement in the treatment of the patient and the safety of the medical device. Hence, the compliance burden on manufacturers has increased.
Consequently, some products have been delayed on entering the market causing changes in the dynamics of the whole segment. Nevertheless, companies that are successful in meeting the said regulations can have the advantage of being competitive by using products that already meet the high-quality standards. In developing regions like India and China, the legal framework is being adjusted in such a way that it comes in line with international standards. The main penalty of these changes is outlined in patient safety while the additional requirements could mean a necessity for the reconfiguration of the manufacturers' compliance. Some countries have imposed price controls on medical devices that complicate further the companies’ access to the market as they are confronted with making these devices affordable and profitable simultaneously.
The forecast for the angioplasty balloons market over the next years is that it will be filled with developments in material design and drug delivery technologies. Manufacturers' focus is on bioresorbable balloons that can soften and thus will not need a permanent insert. These innovations are likely to change the way cardiovascular diseases are treated by providing higher long-term patient success. The market will also benefit from the use of AI-driven diagnostic tools in cardiology. AI-powered by imaging systems during procedures and real-time guidance give precise diagnosis and better selection of the patient and treatment planning.
With more hospitals and healthcare providers adopting AI-based technologies, the operation rates of angioplasty are expected to increase as well as the efficiency of treating the patients. An additional major development will be the more frequent angioplasty procedures performed in outpatient settings. The new technology in the balloon catheter and the new methods of recovery allow more surgeries to be done in ambulatory surgical centers (ASCs). On the one hand, cost is a barrier for patients, but on the other hand, the easier access to treatment is the main benefit, especially in areas with fewer healthcare facilities.
Collaborations between medical device manufacturers and pharmaceutical companies, as well as research institutions, will be key in ushering the industry to the next level of angioplasty balloon technology. From both a resource and capability standpoint, these tie-ups will significantly speed up the development of the latest solutions, thus the presence of angioplasty as a major treatment method for cardiovascular diseases shall be ensured to remain.
The report offers a comprehensive study of the following market segments and their leading categories:
According to Ashutosh, Senior Research Analyst, 6Wresearch, North America will be the one to dominate the market according to the prediction, which is largely attributed to the prevalence of cardiovascular diseases, well-established healthcare systems, and strong presence of major companies. The region has a competitive edge in terms of healthcare science, an increasing number of the aging population, and the policy of angioplasty reimbursement. Among the United States, the one that dominates the market is the one due to high adoption rates of drug-eluting balloons and the advanced practices of interventional cardiology.
The drug-eluting balloons (DEBs) category is set to see substantial growth, given that drug-eluting balloons have now become a much safer alternative to the traditional stents containing antiproliferative drugs which are directly and locally delivered to the arterial wall. DEBs help in the restenosis risk which then leads to a better life for patients because it does not require repeat interventions. Based on the growth of clinical evidence that supports the benefits, DEBs are going to be used more widely and not only for coronary but also for peripheral angioplasties too.
The messy cause of this problem is the escalating rates of coronary artery disease around the world. Furthermore, the topic of overweight people, diabetics, and smokers who produce the CAD is very critical to the contention of the need for like angioplasty health care options. These new balloon technologies of Coronary angioplasty is going to play a big part in controlling the cardiovascular disorders as well as in scrutinizing and reducing mortality rates.
The majority of angioplasty procedures are conducted by hospitals and therefore, they are expected to be the main end-use segment for angioplasty balloons. An advantage of the hospitals is that they are equipped by modern cardiac catheterization labs and have highly skilled interventional cardiologists who hold the highest positions in complex angioplasty cases. On the other hand, the market position will be strengthened by the increasing tendency towards minimally invasive surgeries that take place in outpatient clinics and specialized cath labs. The companies involved in the global angioplasty market are Abbott Laboratories, Boston Scientific Corporation, COVIDIEN LP, Terumo Corporation, and VOLCANO CORPORATION. Outpatient clinics with cath labs in the future are expected to increase demand ease after the prolonged healing duration since the equipment fill-ups have been done off-peak hours on a regular basis.
The report offers a comprehensive analysis of the following market segments
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Global Angioplasty Balloons Market Overview |
3.1 Global Regional Macro Economic Indicators |
3.2 Global Angioplasty Balloons Market Revenues & Volume, 2021 & 2031F |
3.3 Global Angioplasty Balloons Market - Industry Life Cycle |
3.4 Global Angioplasty Balloons Market - Porter's Five Forces |
3.5 Global Angioplasty Balloons Market Revenues & Volume Share, By Countries, 2021 & 2031F |
3.6 Global Angioplasty Balloons Market Revenues & Volume Share, By Type, 2021 & 2031F |
3.7 Global Angioplasty Balloons Market Revenues & Volume Share, By Application, 2021 & 2031F |
3.8 Global Angioplasty Balloons Market Revenues & Volume Share, By End-use, 2021 & 2031F |
4 Global Angioplasty Balloons Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Global Angioplasty Balloons Market Trends |
6 Global Angioplasty Balloons Market, 2021-2031 |
6.1 Global Angioplasty Balloons Market, Revenues & Volume, By Type, 2021-2031 |
6.2 Global Angioplasty Balloons Market, Revenues & Volume, By Application, 2021-2031 |
6.3 Global Angioplasty Balloons Market, Revenues & Volume, By End-use, 2021-2031 |
7 North America Angioplasty Balloons Market, 2021-2031 |
7.1 North America Angioplasty Balloons Market, Revenues & Volume, By Type, 2021-2031 |
7.2 North America Angioplasty Balloons Market, Revenues & Volume, By Application, 2021-2031 |
7.3 North America Angioplasty Balloons Market, Revenues & Volume, By End-use, 2021-2031 |
8 Latin America Angioplasty Balloons Market, 2021-2031 |
8.1 Latin America Angioplasty Balloons Market, Revenues & Volume, By Type, 2021-2031 |
8.2 Latin America Angioplasty Balloons Market, Revenues & Volume, By Application, 2021-2031 |
8.3 Latin America Angioplasty Balloons Market, Revenues & Volume, By End-use, 2021-2031 |
9 Latin America Angioplasty Balloons Market, 2021-2031 |
9.1 Latin America Angioplasty Balloons Market, Revenues & Volume, By Type, 2021-2031 |
9.2 Latin America Angioplasty Balloons Market, Revenues & Volume, By Application, 2021-2031 |
9.3 Latin America Angioplasty Balloons Market, Revenues & Volume, By End-use, 2021-2031 |
10 Asia Pacific Angioplasty Balloons Market, 2021-2031 |
10.1 Asia Pacific Angioplasty Balloons Market, Revenues & Volume, By Type, 2021-2031 |
10.2 Asia Pacific Angioplasty Balloons Market, Revenues & Volume, By Application, 2021-2031 |
10.3 Asia Pacific Angioplasty Balloons Market, Revenues & Volume, By End-use, 2021-2031 |
11 Middle East Angioplasty Balloons Market, 2021-2031 |
11.1 Middle East Angioplasty Balloons Market, Revenues & Volume, By Type, 2021-2031 |
11.2 Middle East Angioplasty Balloons Market, Revenues & Volume, By Application, 2021-2031 |
11.3 Middle East Angioplasty Balloons Market, Revenues & Volume, By End-use, 2021-2031 |
12 Africa Angioplasty Balloons Market, 2021-2031 |
12.1 Africa Angioplasty Balloons Market, Revenues & Volume, By Type, 2021-2031 |
12.2 Africa Angioplasty Balloons Market, Revenues & Volume, By Application, 2021-2031 |
12.3 Africa Angioplasty Balloons Market, Revenues & Volume, By End-use, 2021-2031 |
14 Global Angioplasty Balloons Market Key Performance Indicators |
14 Global Angioplasty Balloons Market - Opportunity Assessment |
14.1 Global Angioplasty Balloons Market Opportunity Assessment, By Countries, 2021 & 2031F |
14.2 Global Angioplasty Balloons Market Opportunity Assessment, By Type, 2021 & 2031F |
14.3 Global Angioplasty Balloons Market Opportunity Assessment, By Application, 2021 & 2031F |
14.4 Global Angioplasty Balloons Market Opportunity Assessment, By End-use, 2021 & 2031F |
15 Global Angioplasty Balloons Market - Competitive Landscape |
15.1 Global Angioplasty Balloons Market Revenue Share, By Companies, 2024 |
15.2 Global Angioplasty Balloons Market Competitive Benchmarking, By Operating and Technical Parameters |
17 Company Profiles |
18 Recommendations |
19 Disclaimer |